Infertility Clinical Trial
— FIDO-DK/RHOfficial title:
Prospective, Longitudinal Study of 800 Recreational Athletes With Current and Former Use of Performance and Image Enhancing Drugs (PIED), Focusing on Androgenic Anabolic Steroids (AAS) - Rigshospitalet
NCT number | NCT05599438 |
Other study ID # | H-21035759 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 14, 2022 |
Est. completion date | June 1, 2040 |
The aim of this prospective longitudinal study is to investigate the risks associated with use of anabolic steroids in fitness circles in Denmark in order to assess the scope of therapeutic need existing as a consequence of use. The objectives are: - To assess long-term complications and outcomes related to: cardiovascular disease, diabetes, gonadal disease (women and men) and psychiatric disease using data from Danish registries including addressing central questions such as whether the following characteristics play a role for development of overt disease - Characterization of illicit AAS use among men and women - Current male reproductive health - Current psychological well-being, aggressive tendencies, cognitive function and quality of life - Current cardiovascular and metabolic status The participants will undergo: - Semi-structured medical interview - Physical examinations - Questionnaires - Blood and urine sampling - Dual X-ray Absorptiometry With a subset undergoing further testing, including semen analysis, gonadotropin-releasing hormone (GnRH) and human chorionic gonadotropinm (hCG) stimulation and 82Rubidium positron emission tomography and computer tomography (PET/CT). Register-based follow-up is planned every third year until the 15th year, marking the completion of the trial. The study will include 800 participants with current or former AAS use and 100 participants (80 male; 20 female) as controls with no former or current use of AAS.
Status | Recruiting |
Enrollment | 900 |
Est. completion date | June 1, 2040 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male and female recreational athletes (=18 years of age) with current or former illicit use (>3 months since AAS cessation) of PIEDs (e.g. AAS) for a minimum four weeks Inclusion Criteria (Controls, n = 100): - Male (n=80) or female (n=20) recreational athletes (=18 years of age) with NO current or former illicit use of AAS. Exclusion Criteria: - Severe psychiatric or somatic diseases which makes it impossible to give informed consent or comply with the investigatory program. - Known pregnancy. |
Country | Name | City | State |
---|---|---|---|
Denmark | Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Caroline Michaela Kistorp | Body Identity Clinic, Odense, Denmark, Centre for Preventative Doping Research at the German Sport University Cologne, Germany, Copenhagen University Hospital - Bispebjerg and Frederikssberg, Copenhagen, Denmark, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Anthropometry of the body composition of current and former users of AAS | Analysis on group-differences in lean and fat mass evaluated by Dual X-ray Absorptiometry | Baseline comparison on entire cohort when initial completion is achieved (Date of primary completion) | |
Other | Extensive examination of the mental health of current and former users of AAS using questionnaires | Analysis on group-differences in response to questionnaires between current, former users of AAS and healthy controls (Questionnaires and further description found in protocol) | Baseline comparison on entire cohort when initial completion is achieved (Date of primary completion) | |
Other | Extensive clinical characterization of current and former users of AAS | Analysis on group-differences in clinical characteristics between current, former users of AAS and healthy controls (Measures and further description found in protocol) | Baseline comparison on entire cohort when initial completion is achieved (Date of primary completion) | |
Other | Extensive biochemical profile of current and former users of AAS | Analysis on group-differences in biochemical measures in blood and urine between current, former users of AAS and healthy controls (Measures and further description found in protocol) | Baseline comparison on entire cohort when initial completion is achieved (Date of primary completion) | |
Primary | Cardiovascular composite endpoint | Register-based composite of mortality, stroke, myocardial infarction, hospitalization due to heart failure and significant cardiovascular disease (See protocol) | 15 years | |
Secondary | Fertility-related composite endpoint | Register-based composite of diagnoses related to fertility and testicular/ovarian function | 15 years | |
Secondary | Metabolism-related composite endpoint | Register-based composite of diagnosis related to impaired metabolic function (See protocol) | 15 years | |
Secondary | Mental health-related composite endpoint | Register-based composite of diagnosis related to psychiatric diagnosis (See protocol) | 15 years | |
Secondary | Male fertility | Substudy analysis on difference in motile sperm count between groups (n=280 male participants; [current/former/controls] 60/60/80) | Baseline comparison when substudy is completed (expected 2023) | |
Secondary | Myocardial flow reserve | Substudy analysis on differences in myocardial flow reserve across groups (n=150 participants; male [current/former/controls]: 30/30/30; female [current/former/current]: 20/20/20) | Baseline comparison when substudy is completed (expected 2023) | |
Secondary | hCG stimulation test | Substudy analysis on difference in response to hCG stimulation test (n=60 male participants [former/controls]: 30/30) | Baseline comparison when substudy is completed (expected 2023) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A |